Recombinant human growth hormone increases albumin and prolongs survival in patients with chronic liver failure: a pilot open, randomized, and controlled clinical trial.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

Who Took Part

The abstract describes 56 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Fifteen healthy subjects served as normal controls.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

Symptoms and complications were recorded.

The prognosis was analysed by Kaplan-Meier survival analysis.

The serum GH, IGF-1, IGFBP-3, and insulin levels were determined using ELISA.

What Was Measured

The subject headings attached to it are Albumins, Biomarkers, China, Cholesterol, Chronic Disease, Enzyme-Linked Immunosorbent Assay and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 56 patients.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver), a journal based in Netherlands.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.